ReviewFuture science OA2015
Nanomedicine as a strategy to fight thrombotic diseases.
Review in Future science OA, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 38 citations in OpenAlex.
- Nanosystems in Cardiovascular Medicine: Advancements, Applications, and Future Perspectives.Pharmaceutics · 2023Review
- Nanotechnology in Stroke: New Trails with Smaller Scales.Biomedicines · 2023Review
- Theranostic Nanomedicines for the Treatment of Cardiovascular and Related Diseases: Current Strategies and Future Perspectives.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Composition and Organization of Acute Ischemic Stroke Thrombus: A Wealth of Information for Future Thrombolytic Strategies.Frontiers in neurology · 2022Review
- Iron Oxide Nanoparticles in Regenerative Medicine and Tissue Engineering.Nanomaterials (Basel, Switzerland) · 2021Review
- Synthetic high-density lipoproteins loaded with an antiplatelet drug for efficient inhibition of thrombosis in mice.Science advances · 2020Article
- Nanoparticle-Mediated Drug Delivery for the Treatment of Cardiovascular Diseases.International journal of nanomedicine · 2020Review
- Effects of PEGylation on capture of dextran-coated magnetic nanoparticles in microcirculation.International journal of nanomedicine · 2019Article
- From design to the clinic: practical guidelines for translating cardiovascular nanomedicine.Cardiovascular research · 2018Review
- Drug Delivery and Nanoformulations for the Cardiovascular System.Research & reviews. Drug delivery · 2017Article
- Welcome to volume 2 ofFuture science OA · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review highlights the preclinical and clinical research based on the use of nano- and micro-carriers in thrombolytic drug delivery. Ischemic heart and stroke caused by thrombosis are the main causes of death in the world. Because of their inactivation in the blood, high doses of thrombolytics are administered to patients, increasing the risk of intracranial hemorrhage. Preclinical research conducted with lipid, polymer or magnetic nanoparticles loaded with thrombolytic drugs showed an enhancement of thrombolysis and a reduction of undesirable side effects. Targeted nanocarriers exhibited an increased accumulation into clot. Clinical trials were already conducted with lipid-based microbubbles combined with ultrasound and thrombolytic drug and showed thrombolysis improvement. Future validation of nanosystems is awaited in clinic. This research opens new strategies for the management of thrombotic diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.